Role of inflammatory pathways in the development and cardiovascular complications of type 2 diabetes.

被引：14
|
作者：
Huerta M.G. [1 ]
Nadler J.L. [1 ]
机构：
[1] 1st Floor Room #1220, Division of Endocrinology and Metabolism, University of Virginia, Fontaine Research Park, Fontaine Medical Research Building, P.O. Box 801405, 450 Ray C. Hunt Drive, Charlottesville, 22908-1405, VA
来源：
Current Diabetes Reports | 2002年 / 2卷 / 5期
关键词：
Pravastatin; Ramipril; Troglitazone; Early Atherosclerotic Lesion; Insulin Resistance Atherosclerosis Study;
D O I：
10.1007/s11892-002-0103-5
中图分类号：
学科分类号：
摘要：
Experimental and epidemiologic studies support the role of inflammation in the development of type 2 diabetes and atherosclerosis. Serum levels of inflammatory markers, in particular highly sensitive C-reactive protein, have been found to be strong predictors of increased risk for type 2 diabetes and cardiovascular disease independent of traditional risk factors. A beneficial effect of thiazolidinediones, angiotensin-converting enzyme inhibitors, and statins in the prevention of type 2 diabetes and cardiovascular events has recently been reported, and potential anti-inflammatory mechanisms of action for these compounds have been described. Prospective, randomized clinical trials are currently underway to confirm these initial findings and define indications for treatment of patients at risk.
引用
收藏
页码：396 / 402
页数：6
相关论文
共 50 条
  • [21] Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
    Nedosugova, L., V
    DIABETES MELLITUS, 2013, 16 (02): : 26 - 35
  • [22] Epidemiology of cardiovascular complications in type 2 diabetes mellitus
    J. B. Meigs
    Acta Diabetologica, 2003, 40 : s358 - s361
  • [23] Metabolomics and risk of cardiovascular complications in type 2 diabetes
    Kuo, S.
    Li, D.
    Chen, Z.
    Yoshida, T.
    Yoshida, Y.
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2024, 367 : S400 - S400
  • [24] Epidemiology of cardiovascular complications in type 2 diabetes mellitus
    Meigs, JB
    ACTA DIABETOLOGICA, 2003, 40 (Suppl 2) : S358 - S361
  • [25] Plasma homocysteine and chronic complications in type 1 diabetes.
    Hermans, MP
    Jamart, J
    Dramais, AS
    Wallemacq, P
    Buysschaert, M
    DIABETOLOGIA, 2001, 44 : A308 - A308
  • [26] The role of eIF2-alpha phosphorylation in Type 2 Diabetes.
    Patel, V.
    Chambers, J. E.
    Marciniak, S. J.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [27] Nephropathy in type 2 diabetes.
    Vandor, T
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (06): : 441 - 441
  • [28] The role of education and weight reduction in control of Type 2 diabetes.
    Nikousokhan, AK
    Rajab, A
    DIABETOLOGIA, 2003, 46 : A87 - A87
  • [29] The role of glitazones in management of type 2 diabetes. A DREAM or a nightmare?
    Lindberg, M.
    Astrup, A.
    OBESITY REVIEWS, 2007, 8 (05) : 381 - 384
  • [30] Novel Inflammatory Pathways Linked to Type 1 Diabetes Development
    Green-Mitchell, Shamina M.
    Grzesik, Wojciech J.
    Weaver, Jessica R.
    Chakrabarti, Swarup K.
    Leone, Kendall A.
    Raab, Rebekah M.
    Taylor-Fishwick, David A.
    Nadler, Jerry L.
    Morris, Margaret A.
    DIABETES, 2011, 60 : A72 - A72
12345